微信小陈
微信小章| 产品名称： | DAL K45 |
|---|---|
| 商品货号： | TS212278 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | carcinoma |
| Applications： | The hybridoma cell line DAL K45 secretes a mouse monoclonal antibody (IgG1) reactive with human renal cell carcinoma; it does not react significantly with normal tissues. This antibody as well as DAL K20 (ATCC CRL-2288) and DAL 29 (ATCC CRL-2291) is useful for identifying kidney differentiation antigens and has been shown effective in radioimaging as well as tumor growth inhibition in xenograft models. The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human renal cell carcinoma |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human renal cell carcinoma |
| Comments： | The hybridoma cell line DAL K45 secretes a mouse monoclonal antibody (IgG1) reactive with human renal cell carcinoma; it does not react significantly with normal tissues.
DAL K45 precipitates molecules with molecular weighs of 177,000 and 150,000 from extracts of surface-labeled Caki-1 (ATCC HTB-46) cells.
This antibody as well as DAL K20 (ATCC CRL-2288) and DAL 29 (ATCC CRL-2291) is useful for identifying kidney differentiation antigens and has been shown effective in radioimaging as well as tumor growth inhibition in xenograft models.
The line was produced by fusing SP2 myeloma cells with spleen cells from BALB/c mice that had been immunized with the Caki-1 clear cell kidney carcinoma cell line. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh Medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2xa0 x 105 viable cells/mL.xa0 Maintain cultures at a cell concentration between 1 x 105 and 1 x 106 cells/mL. Do not allow the cell concentration to exceed 1 x 106 cells/mL. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 |
| Name of Depositor： | SJ Luner, T Ghose |
| References： | Luner SJ, et al. Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma. Cancer Res. 46: 5816-5820, 1986. PubMed: 3530441 Guha AK, et al. Tumor localization of monoclonal antibodies against human renal carcinoma in a xenograft model. Cancer Lett. 61: 35-43, 1991. PubMed: 1764696 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |